IMI Site Tue, 30 Nov 2021 12:02:22 +0000 en-US hourly 1 IMI Site 32 32 Startups use technology, “gamification” for public health issues Tue, 30 Nov 2021 12:02:22 +0000

Wellth, founded in 2014, seeks the answers using behavioral economics, which takes into account individual biases and how they affect decision making. Users can earn small payments, funded by Wellth clients which include medical groups and insurance companies, for things like taking their medications daily, a “gamified” feature that encourages addictive behaviors.

Sequences can save attendees more money – which can only be spent on things like groceries, household needs, home repairs, and auto costs – and users can spin a ‘prize wheel. Every few days for a chance to win bigger winnings. Gamification is frequently used by fintech and other tech companies to disrupt traditional business models and capture market share.

Wellth has raised more than $ 11 million in recent years, has tens of thousands of users, and has reduced hospitalization rates by up to 40% in some populations, Loper said.

So-called digital health companies are attracting more and more capital, according to Megan Zweig, chief operating officer of the Rock Health seed fund. In the first nine months of 2021, these companies made more than $ 20 billion in venture capital investments, up from $ 14.6 billion in 2020 and $ 7.9 billion in 2019, the company said. .

It remains to be seen whether digital health will lead to better health outcomes, Zweig said, but the industry is already changing the way people think about healthcare.

Source link

TRACON Pharmaceutical (TCON) announces regulatory approval of Envafolimab in China Mon, 29 Nov 2021 13:09:04 +0000

Receive instant alerts for news on your actions. Claim your 1-week free trial for Street Insider Premium here.

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel, targeted cancer therapies and using a profitable, CRO-independent product development platform to partner with companies company to develop and market innovative products in the United States, today announced that its partners Alphamab Oncology (stock code: 9966.HK) and 3D Medicines (Beijing) Co., Ltd. announced that envafolimab (KN035), the world’s first single domain PD-L1 antibody formulated for subcutaneous injection, has received marketing authorization from the Chinese National Medical Products Administration (NMPA).

Envafolimab has been approved for use in adult patients with advanced solid tumors with high microsatellite instability (MSI-H) or MisMatch-deficient repair (dMMR), including patients with advanced colorectal cancer who have experienced progression of disease after treatment with fluoropyrimidine, oxaliplatin and irinotecan, as well as patients with other advanced solid tumors who have experienced disease progression after previous systemic therapy and have no satisfactory alternative treatment options.

Prior to this approval, all marketed PD-1 and PD-L1 antibody drugs required intravenous infusions. As a subcutaneously administered PD-L1 antibody, envafolimab can be administered within 30 seconds in the doctor’s office, increasing convenience, shortening the duration of treatment, and preventing patients from the risk of related reactions. to the infusion.

In a pivotal Phase 2 clinical study in patients with advanced dMMR / MSI-H tumors who received one or more lines of treatment, envafolimab demonstrated an objective response rate (ORR) by independent, blinded radiographic examination ( BIRR) by 44.7%, including 12 (11.7%) cases of complete response. Responses were durable, with a duration of response of 12 months in responder patients with advanced colorectal cancer (CRC), advanced gastric cancer, other advanced solid tumors and 89%, 100%, 100 % and 93%, respectively. . The median progression-free survival was 11.1 months and the 12-month overall survival rate was 73.6%. The BIRR-confirmed ORR in patients with MSI-H / dMMR CRC treated with envafolimab who failed fluoropyrimidine, oxaliplatin, and irinotecan was 32%, which was similar to the reported 28% of confirmed ORRs. in the OPDIVO® package leaflet in MSI-H / dMMR Patients with CRC who have failed fluoropyrimidine, oxaliplatin and irinotecan therapy and the confirmed 33% ORR reported for KEYTRUDA® in patients with MSI-H / dMMR CRCs who failed treatment with fluoropyrimidine, oxaliplatin and irinotecan in Cohort A of the Phase 2 KEYNOTE-164 trial. Envafolimab was well tolerated in this study and there were no reports of immune-related pneumonia, immune-related colitis or immune-related nephritis.

“We are delighted that the dedication of our partners Alphamab Oncology and 3D Medicines has resulted in the initial approval of the first subcutaneously administered checkpoint inhibitor,” said Charles Theuer, MD, Ph.D., president and CEO of TRACON. “It is important to note that the TRACON-sponsored ENVASARC pivotal trial of envafolimab for the treatment of pleomorphic undifferentiated sarcoma (UPS) and myxofibrosarcoma (MFS) in the United States continues to perform well at 26 sites, and we look forward to the Independent Data Monitoring Committee’s review. intermediate efficacy and safety data before the end of the year.

Fuzzy Raises $ 44 Million in Funding to Make Digital Veterinary Care More Accessible Than Ever Mon, 29 Nov 2021 02:07:09 +0000

Fuzzy, a San Francisco-based veterinary startup, closed a $ 44 million funding round to deliver exceptional 24/7 digital veterinary care to pet owners with a simple and affordable membership.

The funding round was led by Icon Ventures with participation from existing investors such as Greycroft, Matrix and Crosscut. Several veterinary clinic groups in the US, UK and Germany, as well as angel investors like Mark Vadon and Jose Feliciano, also participated. This brings the total funding raised by Fuzzy to $ 80.5 million. Tom Mawhinney, general partner at Icon Ventures, referred to the company’s involvement, saying:

“Fuzzy is rethinking the way pets and their owners receive veterinary care in a way that improves results and takes the strain off veterinarians themselves. We believe telemedicine and Fuzzy’s lifelong approach to care will transform pet ownership for millions of homes in the United States and around the world, the same way telemedicine has reshaped for the better. patient and physician care.

Fuzzy was founded with a mission to expand access to veterinary health and preventative pet health education for millions of pet parents. The startup achieves this by using proprietary and innovative telemedicine software to connect users to experienced professionals while shipping medication, food, and supplements to pet parents. Zubin Bhettay, co-founder and CEO of Fuzzy, said of this assignment:

“Pet care has become so expensive that it leads to incredibly sad statistics regarding euthanasia and abandonment of pets. With the explosion in pet adoption, we have also seen veterinary clinics overrun, leading to scarcity of appointments and veterinarian burnout. We believe the industry needs to find new ways to reduce the pressure on veterinarians and use technology to deliver care efficiently, where possible. Fuzzy allows veterinary clinics to free up their schedules and use their time more productively.

According to the American Pet Products Association, a total of $ 103 billion has been spent on pet-related expenses in the United States, with more than 90.5 million households owning a pet. Fuzzy seeks to capitalize on the growing number of pet owners not only by operating in over 25 locations, but also by providing high quality service and convenience, while helping the increasingly exhausted veterinary community to better manage his schedules.

Source link

Sanitary sewer overflow at Piney Point Sun, 28 Nov 2021 16:56:46 +0000

Currently, teams from the St. Mary’s County Metropolitan Commission are on site to repair a sanitary sewer overflow at 16979 and 16995 Piney Point Road, Piney Point Maryland 20674.

This overflow is concentrated in the ditch line due to a broken sewer line. We expect the repairs to be completed this afternoon.

Contact with the public of any standing water in the area of ​​the above addresses should be avoided for ten days. Signs “No contact with water” have been installed in the surrounding area. There is no threat of contamination of the local drinking water supply.

David M. Higgins was born in Baltimore and raised in southern Maryland. He has been passionate about journalism since high school. After spending many years in the hospitality industry, he started working in … Read more by David M. Higgins II, Editor / Editor

Source link

Can pregnant women use marijuana? Here’s why drug use increases during pregnancy Sun, 28 Nov 2021 05:00:00 +0000

Legal sales of cannabis, first for medical purposes and now for recreational purposes, have spread across the country. Yet despite what appear to be years of public messages about the idea that marijuana is a fundamentally harmless drug that we needlessly penalize people for using and selling, many Americans still seem uncomfortable with it. encourage its use. And they might be right.

Currently, cities in New York state have until the end of the year to decide whether they wish to allow cannabis dispensaries to operate within their borders. They have every incentive to say yes, including potential millions of dollars in sales tax revenue, but many are revisiting an old slogan: just say no. In New Jersey, according to a analysis of the Rockefeller Institute, three-quarters of “municipalities withdrew from the six categories of adult marijuana licenses (grower, manufacturer, wholesaler, distributor, retailer and delivery) that were described in state law. “

You don’t have to look far to find out why. Take the case of pregnant women: A study published this fall found that children of mothers who use marijuana during or soon after pregnancy are twice as likely as other children to become anxious, aggressive or hyperactive. The National Academy of Sciences Proceedings article describes how researchers looked at the presence of a chemical in the placenta, as well as hair hormone levels in young children, and then measured the performance of these children on a standardized behavioral assessment as well as their heart rate variability.

These are no small results, and they are even more concerning considering that many pregnant women seek marijuana to relieve symptoms of pregnancy, such as nausea. Women “tend to think that smoking and drinking during pregnancy should be avoided at all costs, but cannabis not,” Yoko Nomura, behavioral neuroscientist at City University of New York and co-author of the study, told the New York Times. “We have a long way to go in educating pregnant women, policy makers and even OB-GYN doctors on this issue.”

But where did they get the impression that cannabis is much less dangerous for their health than drinking and smoking? Would it be all government officials? from New Jersey Governor Phil Murphy recently called it was a “world class industry”, and its only concern was that the issue of “fairness” be addressed, meaning that people of all races could share in the profits.

A Kaiser Permanente study in California earlier this year, rates of cannabis use among women in early pregnancy had increased by 25% by the start of the pandemic. While overall state usage has increased over the same time period – around 8% for women – it looks like pregnant women are really benefiting. “Pregnant women are more likely to use cannabis if they are depressed, anxious, or have experienced trauma,” said lead author Kelly Young-Wolff. “It is very possible that more pregnant women will use cannabis in an attempt to cure these problems on their own during the pandemic. ”

Obtaining cannabis for medical purposes has of course been much easier in recent years. While the authors don’t outright blame the legalization, they do note that the results are consistent with the increase in overall cannabis sales in California. According to an article from the Center for Infectious Disease Research and Policy, “State data shows that quarterly average taxable cannabis sales from April to December 2020 were $ 1.2 billion, while the quarterly average for the previous 15 months was $ 712 million, a 68.5% increase. “

But the laws of supply and demand are not the only causes of this problem. It is also the attitude we adopt towards pregnant women when it comes to drugs. Although the public has become widely aware of the problems of babies born exposed to substances – the terrible withdrawal symptoms that plague them during their first few weeks outside the womb – there is also a competing narrative that women who use drugs during pregnancy are victims. and cannot be held responsible for its actions.

Some activists believe that drug use during pregnancy should not be monitored at all. A group called upEnd, which advocates for the abolition of the foster care system because of its racially disparate impact, argues that we should end drug testing of new mothers and infants because it excessively involves and unnecessarily black women in the child welfare system.

Last year, New York City ended drug testing of mothers without their written consent. Lisa Sangoi, co-director and co-founder of the Family Power Movement, noted drug testing “targets black and brown communities for policing, surveillance and control so that white and wealthy people who also use drugs at the same rate are rarely, if ever, monitored.”

Of course, the real solution may be to simply test everyone. And given how much more drug use during pregnancy has become, how much women are now looking for cannabis as a medical intervention, and how much we now realize that it is dangerous for babies, this idea is more. that logical.

Naomi Schaefer Riley is a resident researcher at the American Enterprise Institute, a contributor to Deseret News and author of “No way to treat a child: How the foster care system, family courts and racial activists are destroying young lives. “

Source link

Covid-19: Pharmaceutical companies strive to fine-tune vaccines against new ‘Omicron’ variant Sat, 27 Nov 2021 10:56:50 +0000

The strain, named Omicron and designated a “variant of concern” by the World Health Organization (WHO), reached Belgium after being discovered in South Africa.

The WHO has warned that preliminary evidence suggests the variant has an increased risk of reinfection and may spread faster than other strains.

A number of pharmaceutical companies have said they are working to adapt their vaccines in light of the emergence of Omicron.

Register now to our daily newsletter

Newsletter cut through the noise

File photo dated 12/22/2020 of a Pfizer / BioNTech Covid-19 vaccine (Photo: Danny Lawson / PA)

Health Secretary Sajid Javid said there was “huge international concern” over the strain after banning flights from South Africa, Botswana, Lesotho, Eswatini, Zimbabwe and Namibia to limit its spread.

Mr Javid told MPs the variant could be more transmissible, make existing vaccines less effective and hamper one of the UK’s Covid treatments, Ronapreve.

Ministers were facing calls to go further to prevent a wave of the new variant from arriving in Britain as a Delta wave is underway, with Belgium becoming the first EU country to announce a case.

Professor John Edmunds, who advises the government on the Scientific Advisory Group for Emergencies (Sage), warned that this could create a “very, very, very difficult situation.”

The EU, US and Canada all followed Britain’s decision to impose travel restrictions on visitors to southern Africa before the WHO added the strain, also known as of B.1.1.529, to its highest category for variants of concern.

WHO experts have said there is early evidence suggesting that Omicron has an “increased risk of reinfection” and its rapid spread in South Africa suggests it has a “growth advantage”.

Novavax said it “has already started the development of a novel advanced recombinant protein based on the known genetic sequence of B.1.1.529 and will be ready to start testing and manufacturing in the coming weeks.”

Moderna said: “Since the start of 2021, Moderna has put forward a comprehensive strategy to anticipate the new variants of concern.

“This strategy includes three levels of response if the currently authorized booster dose of 50 µg (micrograms) mRNA-1273 is insufficient to enhance the waning immunity against the Omicron variant.”

Pfizer and BioNTech said that in the event of a variant that could escape the effects of the vaccines, the company expects “to be able to develop and produce a bespoke vaccine against that variant in approximately 100 days, subject to l ‘regulatory approval’.

AstraZeneca said it has “developed, in close collaboration with the University of Oxford, a vaccine platform that allows us to respond quickly to new variants that may emerge” and “is already researching places where the variant has been identified”.

The company is also testing its combined antibody drug against the new variant and hopes that it “will retain its effectiveness because it includes two potent antibodies with different and complementary activities against the virus.”

Professor Sir Andrew Pollard, director of the Oxford Vaccine Group, expressed cautious optimism that existing vaccines might be effective in preventing serious illnesses caused by the Omicron variant.

He told BBC Radio 4’s Today show that most of the mutations are in similar regions seen in other variants so far, adding: “This tells you that despite these mutations existing in other variants , vaccines continued to prevent serious illness over time via Alpha, Beta, Gamma, and Delta.

“At least from a speculative point of view, we have some optimism that the vaccine should still work against a new variant for severe disease, but we really have to wait several weeks for that to be confirmed.

“It is extremely unlikely that a restart of a pandemic in a vaccinated population as we saw last year will occur.”

Professor Pollard said a new vaccine to fight Omicron could start “very quickly” if needed.

“The processes of developing a new vaccine are getting more and more well oiled, so if that is necessary, it is something that could be moved very quickly.”

No cases of the new strain have been detected in the UK, but its arrival in Belgium – after being discovered in Botswana, Hong Kong and Israel – has heightened concerns.

Marc Van Ranst, a virologist at the Rega Institute in Belgium, said a sample was confirmed to be variant in a traveler who returned from Egypt on November 11 before showing symptoms for the first time 11 days later.

The six African countries were added to the UK travel red list on Thursday evening and passengers arriving in the UK from these countries from 4 a.m. on Sunday will be required to book and pay for an approved hotel quarantine by the government for 10 days.

Downing Street urged anyone who has recently arrived from these countries to get tested.

Mr Javid said discussions were underway on the prospect of adding more countries to the red list, telling the Commons that the government “will not hesitate to act if we need to”.

Boris Johnson had a telephone interview with South African President Cyril Ramaphosa on Friday afternoon after Foreign Minister Naledi Pandor said the flight ban “appeared to have been rushed”.

The Prime Minister “commended South Africa’s rapid genomic sequencing” and its “leadership in transparent sharing of scientific data,” Downing Street said.

“They discussed the challenges posed globally by the new variant of Covid-19 and ways to work together to address it and reopen international travel,” a statement read.

Professor Edmunds said the new strain “is of huge concern” and “all data suggests” that it would be able to evade current immunity.

“We are concerned that it will to a large extent,” he told BBC Radio 4’s PM program.

Professor Edmunds urged ministers to consider extending travel restrictions and to prepare a plan to deal with Omicron because “at some point we will have this variant here in the UK”.

Professor Calum Semple, another Sage adviser, told BBC Breakfast: ‘If you can slow the entry of the virus into the country because you are timed for the recall campaign to get ahead of it, and that (then ) lets scientists see if there is anything to worry about, which it does not appear to be.

“The virus will come here by hook or by crook, eventually it will come here because people are asymptomatic, but that doesn’t mean we shouldn’t try to slow it down. “

He said he was an advocate for masks and hand washing and said: “I feel particularly uncomfortable in public transport. I am pro-mask in shops and public transport. We still have high levels of coronavirus but the vaccines work. “

Professor Semple encouraged people to get vaccinated against the coronavirus.

Professor Brendan Wren, of the London School of Hygiene and Tropical Medicine, said people should “stay calm and not overreact”, adding that scientists can “easily modify vaccines to respond to new variants” .

Optimistically in the Daily Mail, he wrote: “In the arms race against the virus, humanity is winning – and we are well prepared. This is not the last time that another variant will see the light of day.

“In the meantime, it is essential to remember to remain calm and not to overreact.”

It is thanks to our loyal readers that we can continue to provide you with the reliable news, analysis and information that matters to you. For unlimited access to our unparalleled local reporting, you can purchase a subscription here and help support the work of our dedicated team of journalists.

Veterinary Pharmaceuticals Market 2021-2026 Detailed Analysis and Growth Strategies, Regional and Recent Scenario Analysis Sat, 27 Nov 2021 04:51:30 +0000

The last Veterinary Pharmaceuticals Market The research report involves an in-depth examination of important aspects such as the global demand, scope, merchantability, profitability and potential of this industrial sphere over 2021-2026. In addition, it emphasizes the different submarkets and reveals the main growth avenues, followed by an in-depth examination of the competitive landscape.

According to experts, the Veterinary pharmaceuticals Industry size is expected to generate notable returns over the analysis period, registering a XX% CAGR throughout.

In addition to hosting verifiable projections, the research literature also provides the latest information on acquisitions, partnerships, mergers, as well as growth strategies deployed by key players to help stakeholders formulate business plans. solid action for the future.

Request a copy of this report @

Key Features of the Veterinary Pharmaceuticals Market Report:

  • Implications of the Covid-19 pandemic on the progression of the industry
  • Records of total sales, overall returns and market share
  • Key industry trends
  • Profitable prospects
  • Growth rate assessments for market and submarkets
  • Positive and negative points associated with using direct and indirect sales channels
  • Leading distributors, resellers and traders

Types of products: veterinary biologics, veterinary preparations and others

  • Price models for each type of product
  • Market share estimate based on sales and returns accumulated by each market segment

Range of applications: poultry, pets and others

  • Product price according to scope of application
  • Revenue and sales accumulated by each category of applications during the analysis period

Competitive dashboard:

  • Zoetis (Pfizer)
  • Virbac
  • Lily
  • Novartis
  • Merial
  • Vetoquinol
  • Boehringer
  • Bayer
  • This will
  • BIOK
  • Animal health in China
  • JIZHONG Pharmaceutical
  • Lukang Pharma
  • Ringpu
  • Jiangxi Yiling
  • JINYU and Dahuanong Group

  • Commercial summary of listed companies
  • Product and service portfolio of the main players
  • Sales count, pricing models, total revenue, gross margin and market share for each company
  • SWOT analysis of large companies
  • Assessment of industry concentration rate and commercialization rate
  • Top-down analysis of business strategies implemented by leading companies

Veterinary Pharmaceuticals Market Segments Covered In The Report:

Geographic fragmentation:

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy and rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
  • South America (Brazil, Argentina, Colombia and the rest of South America)
  • Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, South Africa and Rest of Middle East and Africa)
  • National assessment of each regional market
  • Accumulated sales, returns earned and industry shares obtained by each regional contributor
  • Revenue and growth rate estimates of each regional market over the forecast span

Major point of the TOC:

Chapter One: Veterinary Pharmaceuticals Market Overview

Chapter Two: Veterinary Pharmaceuticals Market Segment Analysis by Manufacturers

Chapter Three: Veterinary Pharmaceuticals Market Segment Analysis by Sales by Manufacturer

Chapter Four: Veterinary Pharmaceuticals Market Segment Analysis by Region

Chapter Five: Veterinary Pharmaceuticals Market Segment Analysis by Type

Chapter Six: Veterinary Pharmaceuticals Market Segment Analysis by Application

Chapter Seven: Upstream and downstream analysis of veterinary pharmaceuticals

Chapter Eight: Development Trend of Veterinary Pharmaceuticals (2021-2026)

Request customization on this report @

Source link

Kaolin Market USD 5.45 Billion in 2020, Market Growth – CAGR of 4.21% by Reports and Data Fri, 26 Nov 2021 16:00:00 +0000

Reports and data

The growth of the kaolin market is driven by increasing demand from several end user industries such as paper, fiberglass, plastics and rubber and others.

NEW YORK, NY, USA, November 26, 2021 / – The kaolin market is expected to grow from $ 5.45 billion in 2020 to $ 7.55 billion by 2028, at a CAGR of 4, 21%, over the forecast period. The increased consumption of kaolin in various end user industries, such as paper, ceramics and sanitary products, fiberglass, paints and coatings, rubber and plastics, is one of the factors the most important which are expected to drive the growth of the kaolin market.

Ceramic sanitary products such as sinks, shower plates, toilet bowls and bathtubs exhibit characteristics such as corrosion resistance, abrasion resistance and glossy surface finish, making it a superior alternative to steel and other metal products. These products are increasingly used worldwide in residential and commercial buildings. Population growth and improved living standards are also expected to fuel demand for ceramic products. These factors are expected to increase the demand for kaolin and thus drive the growth of the global market during the forecast period.

The initiatives undertaken by the governments of Bangladesh and India to promote literacy are expected to result in a strong demand for paper, thereby boosting the market growth during the forecast period. However, the threat of substituting calcium carbonate for paper production could dampen demand growth in the years to come.

Click here for a free copy of this report (including full table of contents, table and figures) at @

Top 2028 Kaolin Market Players (Market Analysis, Opportunities, Demand, Forecast)
Sedlecký kaolin AS. (Czech Republic) ,. KaMin LLC (United States), Thiele Kaolin Company (United States), EICL Ltd. (India), SCR-Sibelco (Belgium), BASF (Germany), Imerys (France), Ashapura Group (India), Lasselsberger Group (Hungary), Quarzwerke GmbH (Germany) and others.

Other key findings from the report suggest

The Kaolin market is expected to grow from USD 5.45 billion in 2020 to USD 7.55 billion by 2028, at a CAGR of 4.21%, during the forecast period. The increased consumption of kaolin in various end user industries, such as paper, ceramics and sanitary products, fiberglass, paints and coatings, rubber and plastics, is one of the factors the most important which are expected to drive the growth of the kaolin market.

The calcined market is expected to experience the largest growth at USD 2.22 billion in 2028, at a CAGR of 5.1% during the forecast period. Calcined kaolin is used in paint and coatings, ceramics, and in the development of plastic cables. Emerging countries in the Asia-Pacific and South America regions, such as China, India and Brazil, are considered key markets for calcined kaolin.

The paper segment market will hold the largest market and is expected to reach $ 1.80 billion in 2028, at a CAGR of 4.8%. Kaolin improves various properties of the paper, such as ink absorption and ink pigment resistant, low lint tendency and roughness, which in turn improves the printability of the paper. The increasing use of kaolin in paper production is therefore expected to drive the growth of the end-use segment of the paper industry.

The Asia-Pacific (APAC) market is expected to hold the largest market share and reach USD 2.4 billion in 2028, with a CAGR of 5.1%. The increased demand for paper coating materials in emerging markets and the increased use of paper packaging products are key factors contributing to the growth of the paper industry. The growth of the paper industry is expected to boost the demand for kaolin in the Asia-Pacific region. In addition, the increased consumption of ceramics in the construction industry and the high demand for plastics are also contributing to the growth of the kaolin market in this region.

Download the summary:

This report covers the comprehensive upcoming and present trends applicable to the market along with the restrictions and drivers for business development. It offers industry forecasts for the coming years. This research analyzes major markets and their sub-segments, changing patterns and pressures on the industry, strategic perspectives and changing supply and demand situations, quantifies opportunities with market size and forecasts the market, and monitors emerging developments / opportunities / challenges.

Competitive landscape
The global Kaolin market is highly fragmented and major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprint in this market. The report includes the market shares of the Kaolin market for the world, Europe, North America, Asia-Pacific, South America, Middle East & Africa.

To learn more about the report @

Segmentation: global kaolin market

Ceramics and sanitary ware
Paints and coatings

The regional analysis covers:

North America (United States, Canada, Mexico)
Europe (UK, Italy, Germany, France, rest of the EU)
Asia-Pacific (India, Japan, China, South Korea, Australia, rest of APAC)
Latin America (Chile, Brazil, Argentina, rest of Latin America)
Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa, Rest of MEA)

Request Report Customization @

Read more related reports:

Glass Manufacturing Market Sales:

Market demand for proteolytic enzymes:

About Us:
Our in-house experts assist our clients with advice based on their market competence that helps them build a comprehensive database for clients. Our team offers expert advice to clients to guide them in their business plans. We go to great lengths to satisfy our customers and focus on meeting their demands to ensure the end product is what they desire. We excel in various areas of the market and with our services spanning competitive analysis, research and development analysis, and demand estimation, among others, we can help you invest your funds. in the areas most advantageous for research and development.

Tushar Rajput
Reports and data
+1 212-710-1370
write us here
Visit us on social networks:

Source link

New Poll Shows Majority of Massachusetts People Think Cannabis Legalization Is Overall Positive for the State Fri, 26 Nov 2021 12:52:00 +0000

A poll released this week showed that only a fraction of Massachusetts residents believe the legalization of marijuana has had a negative impact on the state.

University of Massachusetts Amherst and WCVB published a poll Monday in which 61% of those polled said legal cannabis for adult use was overall positive for the state. While 25% said it was neither positive nor negative, only 13% said it was negative.

“This poll also shows that legalization reduces the stigma historically associated with cannabis, which will only allow the Commission to continue to make progress in its efforts to ensure full participation in this industry by disproportionately affected communities,” he said. said the chairman of the Cannabis Control Commission, Steven J. Hoffman. in a report. “Our work is far from over, and my colleagues and I will continue to speak out on the solutions needed to ensure Massachusetts lives up to its equity mandate.”

The survey was conducted November 9-16 and included 750 respondents.

On November 8, 2016, voters in Massachusetts approved the legalization, regulation and taxation of cannabis with 1,769,328 voters, or 52%, in favor of Question 4, and 1,528,219 voters, or 45%, in the ‘opposition. Legalization came following the approval of cannabis for medical purposes in 2012 and the decriminalization of small amounts of the plant in 2008.

November 20 marked the third anniversary of the opening of the first adult marijuana retailers in Massachusetts, the first on the East Coast.

Since then, 179 stores have started their activities. A total of 325 adult-use marijuana establishments, including indoor and outdoor growers, product manufacturers, micro-businesses, delivery companies and independent testing labs, have opened, according to the Commission of cannabis control.

The adult use industry generated more than $ 2.3 billion in gross sales during this period, CCC said.

Associated content:

Source link

Capsule Manufacturing in India Boosted by New ACG Mega Facility Thu, 25 Nov 2021 11:09:01 +0000

Global pharmaceutical industry supplier ACG recently announced plans to invest INR 6 billion (USD 80.56 million) to build Asia’s largest capsule manufacturing unit in India (near Aurangabad in the Western State of Maharashtra). This facility will increase India’s industrial capacity to supply high quality, safe and affordable medicines and nutraceuticals globally. ACG was founded in Mumbai in 1961 and is now present worldwide, providing integrated solutions for the pharmaceutical and nutraceutical industries.

Creation of the largest capsule manufacturing plant and research center in Asia

With a presence in more than 138 countries, ACG is the world’s largest integrated supplier of solid dosage products and services – providing hard-shell capsules, film and sheet barrier solutions, tracking and traceability systems and processing, packaging and inspection equipment.

The company has signed a memorandum of understanding with the state government of Maharashtra to produce 40 billion capsules per year, for Indian and international pharmaceutical and nutraceutical companies. The government of Maharashtra has granted “megaproject” status to this company.

According to the announcement, the future facility is expected to create around 1,000 direct and indirect jobs by 2023 in the region. The announcement also mentioned that the proposed plant would use the sustainable design principles of internationally recognized Leadership in Energy and Environmental Design (LEED) and be significantly powered by renewable energy sources.

ACG intends to set new benchmarks in capsule manufacturing and research facility using automation and Industry 4.0 technologies to minimize resource intensity and ensure products meet best practice Global Manufacturing (GMP).

Overview of the Indian pharmaceutical industry

India ranks third in the world in terms of pharmaceutical production by volume and 14e in terms of value. The Indian states of Andhra Pradesh, Gujarat, Maharashtra and Goa are the country’s main pharmaceutical manufacturing hubs. Bulk drug clusters are located in Gujarat (Ahmedabad, Vadodara), Maharashtra (Mumbai, Aurangabad, Pune), Telangana (Hyderabad), Tamil Nadu (Chennai), Karnataka (Mysore, Bangalore) and Andhra Pradesh (Visakhapatnam) .

India’s pharmaceutical sector meets over 50% of global vaccine demand, 20% of global generic demand by volume and 25% of all drugs in the UK.

India’s pharmaceutical industry was estimated at US $ 42 billion in 2021, with a network of around 3,000 pharmaceutical companies and 10,500 manufacturing units. It is also expected to reach US $ 65 billion by 2024 and US $ 120-130 billion by 2030. According to an OECD estimate, the Indian pharmaceutical industry will grow by 317% between 2017 and 2060. to dominate the global pharmaceutical market, followed by Indonesia. .

Some of the major domestic industry players include Sun Pharmaceutical Industries, Cipla, Lupine, Dr. Reddy’s Laboratories, Aurobindo Pharma, Zydus Cadila, Piramal Enterprises, Glenmark Pharmaceuticals, and Torrent Pharmaceuticals.

India’s current foreign direct investment (FDI) policy allows 100% automatic FDI in completely new pharmaceutical projects and 74% automatic in brownfield projects.

In addition, the Indian pharmaceutical market is supported by the following production incentive schemes (PLI) boost domestic manufacturing capacity, including high value-added products along the global supply chain. The executing agency for these programs is the Department of Pharmaceuticals.

  • PLI Scheme for Key Raw Materials (KSM) / Medicines Intermediates (DI) and Active Pharmaceutical Ingredients (API) (PLI 1.0)
  • PLI Regime for Pharmaceuticals d (PLI 2.0)

The Indian Contract Manufacturing Organization (CMO) market

The concept of contract manufacturing has evolved rapidly in India due to the growing presence of multinational pharmaceutical companies.

India has an advantage over countries like Vietnam, China and Ireland in manufacturing drugs and medical products due to the presence of key resources – a large labor market, a technically skilled workforce. qualified and production premises approved by WHO-GMP.

According to the Indian Drug Manufacturers Association, the pharmaceutical contract manufacturing industry in India is growing by 20%, which offers great opportunities for small and medium enterprises (SMEs). The current market value is estimated at 50 percent of national production, which is about 5.3 billion US dollars.

In addition, the Indian CMO market is expected to register a compound annual growth rate (CAGR) of 13.3% during the period 2021-2026, fueled by higher return on investment and therapeutic efficacy. Rising demand for injectable drugs, especially in cancer research, will create higher value in India’s pharmaceutical contract manufacturing market. Injectable drugs offer higher yields compared to other types of drug formulation.

Some of the leading pharmaceutical contract manufacturing companies in India include Gracure Pharmaceuticals Ltd., Nvron Life Science Ltd., Kremoint Pharma Pvt. Ltd., Makcur Laboratories Ltd., etc.

Pharmaceutical R&D in India

According to Statista data, Indian pharmaceutical companies spend less than 13% of their annual turnover on research and development (R&D). In FY2020, the highest R&D spending was made by Lupine at US $ 225 million, followed by Dr Reddy (US $ 204 million) and Cipla (US $ 173 million).

In October 2021, the Department of Pharmaceuticals (DoP) released a draft policy to catalyze R&D in the pharmaceutical and medical technology (pharma-medtech) sector to make India a leader in drug discovery and innovative medical devices. This policy has a ten-year perspective and will be implemented through an action plan defining roles, responsibilities, activities, targets and deadlines. The action plan will then be broken down into five-year and annual activities to facilitate its implementation. A high-level working group will be set up within the DoP to guide and review the implementation of the policy.

The policy project to catalyze research, development and innovation in the Pharma-MedTech sector in India mainly focuses on:

  • Simplify regulatory processes to enable rapid drug discovery and development and innovation in medical devices.
  • Explore mechanisms to incent private sector investment in research, assess various funding mechanisms including budget support, venture capital, CSR funding, etc., and provide tax incentives to support innovation .
  • Strengthening of the R&D ecosystem through increased collaboration between industry and academia in order to develop mechanisms to harmonize research according to industry requirements.

Speaking recently at the Global Innovation Summit hosted by the Indian Pharmaceutical Alliance in November 2021, Amitabh Kant (CEO, NITI Aayog) called on the Indian pharmaceutical industry to focus on R&D and innovation in emerging technologies in the pharmaceutical sector in order to position the Indian pharmaceutical sector. at the top of the global landscape.

About Us

India Briefing is produced by Dezan Shira & Associates. The firm assists foreign investors throughout Asia from offices around the world, including Delhi and Mumbai. Readers can write to for more help on doing business in India.

We also maintain offices or have alliance partners helping foreign investors in Indonesia, Singapore, Vietnam, Philippines, Malaysia, Thailand, Italy, Germany, and the United States, in addition to Bangladesh and Russia.